AGM 130

Drug Profile

AGM 130

Alternative Names: AGM 130

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnyGen
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 11 Mar 2017 AnyGen has patents pending for AGM 130 in USA, Japan, Korea and Europe
  • 10 Mar 2017 Phase-I clinical trials in Breast cancer in South Korea (IV) before March 2017 (AnyGen pipeline, March 2017)
  • 30 Oct 2014 Pharmacodynamics data from a preclinical study in Breast cancer released by AnyGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top